CMBI: Raises Target Price for Sino Biopharmaceutical (01177.HK) to HK$9, Maintains "Buy" Rating

date
17/11/2026
CMBI issued a research report stating that it has raised the target price of Sino Biopharmaceutical (01177.HK) by 3.4%, from HK$8.7 to HK$9, maintaining a "Buy" rating. Considering that the company will continue to realize BD transactions in 2026, the bank has revised its forecasts upward, expecting revenue to grow by 11.5%, 13.2%, and 10.4% year-on-year in 2026, 2027, and 2028, respectively, and adjusted net profit attributable to shareholders to grow by 12.5%, 19.4%, and 9.9% year-on-year, respectively.